 | Up a level |
Gantenbein, Andreas R; Agosti, Reto; Kamm, Christian P; Landmann, Gunther; Meier, Niklaus; Merki-Feld, Gabriele Susanne; Petersen, Jens A; Pohl, Heiko; Ryvlin, Philippe; Schankin, Christoph J; Viceic, Dragana; Zecca, Chiara; Schäfer, Elisabeth; Meyer, Ina; Arzt, Michael E (2022). Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results. The journal of headache and pain, 23(1), p. 161. BioMed Central 10.1186/s10194-022-01530-9
Gantenbein, Andreas R; Agosti, Reto; Kamm, Christian P; Landmann, Gunther; Meier, Niklaus; Merki-Feld, Gabriele Susanne; Petersen, Jens A; Pohl, Heiko; Ryvlin, Philippe; Schankin, Christoph J; Viceic, Dragana; Zecca, Chiara; Schäfer, Elisabeth; Meyer, Ina; Arzt, Michael E (2022). Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results. The journal of headache and pain, 23(1), p. 142. 10.1186/s10194-022-01515-8
Gantenbein, Andreas R; Agosti, Reto; Gobbi, Claudio; Flügel, Dominique; Schankin, Christoph J.; Viceic, Dragana; Zecca, Chiara; Pohl, Heiko (2021). Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia, 41(11-12), pp. 1181-1186. Sage Publications 10.1177/03331024211014616
